Company Filing History:
Years Active: 2025
Title: The Innovations of Toshitaka Futagawa
Introduction
Toshitaka Futagawa is a notable inventor based in Kagoshima, Japan. He has made significant contributions to the field of therapeutic pharmaceuticals, particularly in the treatment of bone and soft tissue tumors. His innovative approach has garnered attention in the medical community.
Latest Patents
Futagawa holds a patent for a therapeutic pharmaceutical composition aimed at treating bone and soft tissue tumors. The patent describes a method that involves administering a conditionally replicating adenovirus containing an E1A gene under the expression control of a Survivin promoter. This method is designed for subjects in need of such treatment. The conditionally replicating adenovirus is characterized by not being defective in the E3 region. This innovative treatment method showcases Futagawa's commitment to advancing medical therapies.
Career Highlights
Futagawa is associated with Surv Biopharma Inc., where he continues to work on groundbreaking research and development in the field of oncology. His career is marked by a dedication to improving therapeutic options for patients suffering from challenging conditions.
Collaborations
Futagawa collaborates with esteemed colleagues, including Ken-ichiro Kosai and Satoshi Nagano. These partnerships enhance the research efforts and contribute to the development of effective treatments.
Conclusion
Toshitaka Futagawa's work exemplifies the spirit of innovation in the medical field. His patent for a therapeutic pharmaceutical composition represents a significant advancement in the treatment of tumors. Through his career and collaborations, he continues to make a positive impact on healthcare.